Biosimilars for Management of Crohn Disease

Ann Intern Med. 2019 Jan 15;170(2):129-130. doi: 10.7326/M18-3060. Epub 2018 Dec 11.

Authors

Ole Haagen Nielsen¹, Mark Andrew Ainsworth²

Affiliations

¹ University of Copenhagen Herlev Hospital, Herlev, Denmark (O.H.N.).
² Odense University Hospital, Odense, Denmark (M.A.A.).

PMID: 30535358
DOI: 10.7326/M18-3060

No abstract available

Publication types

Editorial

MeSH terms

Biosimilar Pharmaceuticals / economics*
Biosimilar Pharmaceuticals / therapeutic use*
Cost Savings*
Crohn Disease / drug therapy*
Drug Development / economics
European Union
Humans
Infliximab / therapeutic use
Prescription Fees
Tumor Necrosis Factor-alpha / antagonists & inhibitors
United States

Substances

Biosimilar Pharmaceuticals
Tumor Necrosis Factor-alpha
Infliximab